Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Blood (2024) 144 (Supplement 1): 4211.

https://doi.org/10.1182/blood-2024-207143

Published: 2024

Journal Articles

Leukemia Physician's Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia

Yenny Alejandra Moreno Vanegas, Suhaib Younis Mohamed El Khatib, Brooke Hisrich, Alexander Coltoff, Rory M. Shallis, Anand Ashwin Patel, Jan Philipp Bewersdorf, Timothy S. Oh, Yasmin Abaza, Charles Foucar, Aaron D. Goldberg, Adam S. Duvall, Ehab L. Atallah, Mark R. Litzow, Talha Badar

Blood (2024) 144 (Supplement 1): 1487.

https://doi.org/10.1182/blood-2024-205782

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study

Adam Julian Cohen-Nowak, Alexander Coltoff, Anand Ashwin Patel, Ehab L. Atallah, Mobachir El Kettani, John Wang, Emily Symes, Girish Venkataraman, Alexa Siddon, Emily Giever, Rory M. Shallis, Jessica Kaplan Altman, Kirsten Bell-Burdett, Talha Badar, Barina Aqil, Yasmin Abaza

Blood (2024) 144 (Supplement 1): 2801.

https://doi.org/10.1182/blood-2024-199377

Published: 2024

Journal Articles

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Ehab L. Atallah, Moshe Y. Levy, Paul B. Koller, Koji Sasaki, Srinivas K Tantravahi, David Andorsky, Celesteann T Bremer, Joshua F Zeidner, Marlise R. Luskin, Reinhold Munker, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Michael J. Mauro, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 479.

https://doi.org/10.1182/blood-2024-200717

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood (2024) 144 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2024-205812

Published: 2024

Journal Articles

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

Blood (2024) 144 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2024-211623

Published: 2024

Journal Articles

U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Ehab L. Atallah, Michael S. Broder, Onyee Chan, Hannah Dalglish, Kathryn E. Flynn, Jeffrey Gilreath, Marisa Hine, Anthony M. Hunter, Michael J. Mauro, Javier Pinilla-Ibarz, Lindsay A.M. Rein, Neil P. Shah, Evan Stemper, Srinivas K Tantravahi, Jay Yang

Blood (2024) 144 (Supplement 1): 5052.

https://doi.org/10.1182/blood-2024-194617

Published: 2024

Journal Articles

Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

Sameem Abedin, Guru Subramanian Guru Murthy, Mehdi Hamadani, Laura C. Michaelis, Karen-Sue Carlson, Lyndsey Runaas, Katelyn Gauger, Avinash Desai, Mary Chen, Patrik Brodin, Kate L Li, Mojisola Rotibi, Umar Sayeed, Alexandra M. Harrington, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2024-201559

Published: 2024

Journal Articles

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

Ehab L. Atallah, Islam Sadek, David Wei, Dominick Latremouille-Viau, Carmine Rossi, Andrea Damon, Daisy Yang, Remi Bellefleur, Annie Guérin, Kejal Jadhav

Blood (2024) 144 (Supplement 1): 3812.

https://doi.org/10.1182/blood-2024-193201

Published: 2024

Journal Articles

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Jessica Kaplan Altman, Zhuoxin Sun, Alexander E. Perl, Richard Little, Steven D. Gore, Laura C. Michaelis, Geoffrey L. Uy, Yasmin Abaza, Sameem Abedin, John L. Reagan, Ehab L. Atallah, Selina Luger, Mark R. Litzow

Blood (2024) 144 (Supplement 1): 2907.1.

https://doi.org/10.1182/blood-2024-199701

Published: 2024

Journal Articles

Assessment of Outcomes of Allogeneic Stem Cell Transplantation By Treatment Arm in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia Randomized to Conventional Chemotherapy +/- Blinatumomab in the ECOG-ACRIN E1910 Phase III National Clinical Trials Network Trial

Blood (2024) 144 (Supplement 1): 779.

https://doi.org/10.1182/blood-2024-207557

Published: 2024

Journal Articles

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Samuel J. Yates, Julian J. Weiss, Abigail Sneider, Emily Geramita, Guru Subramanian Guru Murthy, Talha Badar, Annie Im, Chenyu Lin, Wei Cheng, Eric S. Winer, Yasmin Abaza, Mark R. Litzow, Ehab L. Atallah, Alok Swaroop, Anand Ashwin Patel, Rory M. Shallis

Blood (2024) 144 (Supplement 1): 447.

https://doi.org/10.1182/blood-2024-207116

Published: 2024

Journal Articles

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Jorge E. Cortes, Michael J. Mauro, Alexis Visotcky, Srinivas K Tantravahi, James E Thompson, Jay Yang, Arielle Baim, Yan Gao, Sonia Maldonado-Schmidt, Claire Olig, Kathryn E. Flynn, Jerald P. Radich, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 6601.

https://doi.org/10.1182/blood-2024-207884

Published: 2024

Journal Articles

Immune-Scape in Myeloid Sarcoma and Acute Myeloid Leukemia

Juliana Alvarez Argote, Kristin E Zorn, Cary Stelloh, Alison E Meyer, Maria E Hintzke, Ashley Cunningham, Emily Giever, George S Vassiliou, Ehab L. Atallah, Sridhar Rao

Blood (2024) 144 (Supplement 1): 1554.

https://doi.org/10.1182/blood-2024-202505

Published: 2024

Journal Articles

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Blood (2024) 144 (Supplement 1): 5174.

https://doi.org/10.1182/blood-2024-198914

Published: 2024

Journal Articles

CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes

Kristine Broge-Reynen, Emily Giever, Aniko Szabo, Ryan Conrardy, Nicole M Held, Laura C. Michaelis, Lyndsey Runaas, Sameem Abedin, Guru Subramanian Guru Murthy, Karen-Sue Carlson, Ravi Kishore Narra, Sumana Devata, Sheila Swartz, Valarie Ehrlich, Mary Rodgers, Allison Johnson, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 5173.

https://doi.org/10.1182/blood-2024-208834

Published: 2024

Journal Articles

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

Blood (2024) 144 (Supplement 1): 993.

https://doi.org/10.1182/blood-2024-201881

Published: 2024

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Guru Subramanian Guru Murthy, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Adam S Duvall, Bijal D. Shah, Arielle Baim, Tyce Kearl, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2023-187721

Published: 2023

Journal Articles

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Blood (2023) 142 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2023-189648

Published: 2023

NARROW

Addition of Blinatumomab to Consolidation Therapy Among Older Newly Diagnosed Patients (pts) with BCR::ABL1 Negative B-Lineage Acute Lymphoblastic Leukemia (ALL) in the ECOG-ACRIN E1910 Randomized Phase III Trial

Leukemia Physician's Perspective on Transplant in Patients with TP53 Mutated Acute Myeloid Leukemia

Clinical Characteristics and Outcomes of Mixed Phenotype Acute Leukemia (MPAL): A Large Multi-Center Retrospective Study

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis

U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Outcome of Patients with TP53 Mutated Relapsed/Refractory AML with Lintuzumab-Ac225 in Combination with CLAG-M Following Venetoclax Plus Hypomethylating Agent Therapy

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) - a Chart Review Study in the United States

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A Myelomatch Treatment Trial: ECOG-ACRIN MM20A-EA02

Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Immune-Scape in Myeloid Sarcoma and Acute Myeloid Leukemia

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

CNS Status at Diagnosis Can Identify Acute Myeloid Leukemia Patients with Poor Induction Outcomes

Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only